March 27th 2026

By Ailsa Colquhoun

Alerts: Sandoz Apixaban 2.5mg and 5mg tablets; Vesomni 6 mg/0.4 mg modified release tablets

MHRA has issued two alerts (note, not recalls):

Eight batches each of Sandoz Limited, Apixaban 2.5mg and 5mg Tablets

Six batches of Quadrant Pharmaceuticals parallel imported packs of Vesomni 6 mg/0.4 mg modified release tablets

Apixaban
Affected batches do not contain up‑to‑date patient information leaflets. Missing information relates to:

• The newly authorised paediatric indication (children aged 28 days to <18 years), and
• Updated guidance regarding use following spinal/epidural catheter removal.

Healthcare professionals are advised to inform patients and carers of the approved dosing advice in relation to catheters.The updated PILs for each strength are available via the Electronic Medicines Compendium (eMC):

• Apixaban Sandoz 2.5 mg film-coated tablets - Patient Information Leaflet (PIL) 13807
• Apixaban Sandoz 5 mg film-coated tablets - Patient Information Leaflet (PIL) 13806

Hard copies of updated PILs are available on request. Please contact sales.sandoz-gb@sandoz.com with your contact details and PIL requirements.  

Vesomni 6 mg/0.4 mg modified release tablets

Six batches of Quadrant Pharmaceuticals’ parallel imported packs of Vesomni 6 mg/0.4 mg modified release tablets feature the incorrect barcode/GTIN on the carton (for parallel imported Solaraze 3% Gel 2 x 25 g packs (containing diclofenac).

Other carton information, including the name, strength and pharmaceutical form of the medicine, and the quality of the tablets, are not impacted by the labelling defect.

Dispensary teams are asked to not use this batch of medicine in robotic or automated dispensing or stocking systems. Manual dispensing and stocking is unaffected.